Shuttle Pharmaceuticals Holdings, Inc. completed a securities purchase agreement with a single investor, raising approximately $2.5 million in gross proceeds. The transaction includes a pre‑funded warrant to purchase up to 625,156 shares of common stock at $4.00 per share, a premium above the Nasdaq market price.
The private placement is expected to close on or about November 4, 2025, subject to customary closing conditions. WestPark Capital, Inc. served as the exclusive placement agent. Net proceeds will be used for marketing, general corporate purposes, and working‑capital needs.
The company’s cash balance was $4.51 million as of March 31, 2025, and its operating expenses have driven a net loss of $3.0 million in Q1 2025. The new equity raise is intended to bridge the funding gap for ongoing Phase 2 trials of its lead radiation‑sensitizing candidate, Ropidoxuridine, and to support corporate initiatives, including a planned acquisition of Molecule.ai.
Shuttle’s market capitalization was approximately $3.18 million at the time of the announcement, and its common stock was trading near its 52‑week low of $2.91. The $4.00 purchase price represents a premium over the market, reflecting the company’s valuation expectations. Placement agent fees and other offering expenses are expected to reduce the net proceeds, but the company has not disclosed the exact amount.
The company has previously raised $4.25 million in June 2025 and $5.0 million in March 2025, both through private placements with WestPark Capital. These prior financings have helped Shuttle maintain compliance with Nasdaq’s minimum stockholders’ equity requirement, though it continues to work toward regaining compliance with the minimum bid price requirement.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.